INVALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Subject who showed medically significant adverse   │ Subject who showed medically significant adverse   │     100 │
│ events or intolerance with aripiprazole during     │ events or intolerance with aripiprazole during     │         │
│ screening period or as prior experiences           │ screening period or as prior experiences           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects with diseases of the central nervous      │ Subjects with diseases of the central nervous      │     100 │
│ system that may impact the assessment of the       │ system that may impact the assessment of the       │         │
│ psychotic symptoms as per investigator's opinion   │ psychotic symptoms as per investigator's opinion   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects with a significant risk of violent        │ Subjects with a significant risk of violent        │     100 │
│ behavior or a significant risk of committing       │ behaviour or a significant risk of committing      │         │
│ suicide based on history or investigator's         │ suicide based on history or investigator's         │         │
│ judgment                                           │ judgment                                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects had a history of seizures, neuroleptic    │ Subjects had a history of seizures, neuroleptic    │     100 │
│ malignant syndrome, clinically significant tardive │ malignant syndrome, clinically significant tardive │         │
│ dyskinesia, or other medical condition that would  │ dyskinesia, or other medical condition that would  │         │
│ expose them to undue risk or interfere with study  │ expose them to undue risk or interfere with study  │         │
│ assessments                                        │ assessments                                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects having any other clinically significant   │ Subjects having any other clinically significant   │     100 │
│ finding of the physical examination or laboratory  │ finding of the physical examination or laboratory  │         │
│ value that make investigator consider that it      │ value that make investigator consider that it      │         │
│ would be inappropriate to participate in this      │ would be inappropriate to participate in this      │         │
│ study                                              │ study                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Male and female legally aged ≥19 and \< 65 years   │ Male and female aged =19 and < 65 years            │      87 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects who have been treated with clozapine,     │ Subjects who have been treated with clozapine or   │      87 │
│ electroconvulsive therapy (ECT) or other long-     │ long-acting injectable antipsychotic drugs within  │         │
│ acting injectable antipsychotic drugs within 3     │ 3 months prior to the screening                    │         │
│ months prior to the screening                      │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects must exhibit willingness, physiologic     │ Subjects must exhibit willingness, physiologic     │      88 │
│ capability, and an educational level sufficient to │ capability, and an educational level sufficient to │         │
│ comply with all protocol procedures as per the     │ comply with all protocol procedures                │         │
│ investigator's judgment                            │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects who need antipsychotic treatment (other   │ Subjects who need antipsychotic treatment (other   │      89 │
│ than clozapine), and would be stable when          │ than clozapine), and would be stable when          │         │
│ switching to Abilify Maintena on the               │ switching to long-acting injectable aripiprazole   │         │
│ investigator's judgement                           │ in the investigator's judgement                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Significant history of drug abuse disorder         │ Significant history of drug abuse disorder         │      92 │
│ (excluding caffeine and nicotine, including        │ (including alcohol, as defined in DSM-5 substance  │         │
│ alcohol, as defined in DSM-5 substance use         │ use disorder or in the opinion of the              │         │
│ disorder or in the opinion of the investigator)    │ investigator) within the last 6 months prior to    │         │
│ within the last 6 months prior to screening        │ screening                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects who participated in another               │ Subjects participating another interventional      │      96 │
│ interventional clinical trial within 30 days prior │ clinical trial within 30 days prior to screening   │         │
│ to screening                                       │                                                    │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ D. CGI-S score ≤4 (moderately ill)                 │ Women who are pregnant, nursing, or who plan to    │      28 │
│                                                    │ become pregnant while in the trial                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ B. Subjects who have no more than a moderate       │ Subjects who take atypical antipsychotic drugs,    │      42 │
│ rating on the PANSS total score≤80 C. 4 individual │ and should be maintained on current antipsychotic  │         │
│ PANSS items, which are concerning to psychotic     │ drugs (including atypical antipsychotic drugs) and │         │
│ symptom (P2. conceptual disorganization, P3.       │ dose for at least 4 weeks prior to the screening   │         │
│ hallucinatory behavior, P6.                        │                                                    │         │
│ suspiciousness/persecution, G9. unusual thought    │                                                    │         │
│ content), score≤4                                  │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnant or lactating women, or women of           │ Subjects having any other clinically significant   │      42 │
│ childbearing potential who are not willing to or   │ finding of the physical examination or laboratory  │         │
│ not able to use contraceptive methods (sexual      │ value that make investigator consider that it      │         │
│ abstinence; oral, implanted or injection hormone   │ would be inappropriate to participate in this      │         │
│ contraceptive methods; intrauterine device or      │ study                                              │         │
│ condom; barrier contraceptive methods such as      │                                                    │         │
│ diaphragm and spermicide), accepted to avoid       │                                                    │         │
│ pregnancy until the end of the clinical trial      │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects with all of the following schizophrenia   │ Subjects participating another interventional      │      49 │
│ clinical features                                  │ clinical trial within 30 days prior to screening   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects who voluntarily consented to              │ Subjects participating another interventional      │      50 │
│ participating in the clinical trial                │ clinical trial within 30 days prior to screening   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 19 Years                  │ Male and female aged =19 and < 65 years            │      50 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Must have maximum age of 64 Years                  │ Male and female aged =19 and < 65 years            │      50 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ (e.g. Aripiprazole≥10 mg/day, Olanzapine≥10        │ Subjects who have been treated over maximum        │      54 │
│ mg/day, Risperidone≥2 mg/day, Quetiapine ≥150      │ maintenance dose (as specified in each label) of   │         │
│ mg/day)                                            │ oral antipsychotics at screening. (e.g.            │         │
│                                                    │ Aripiprazole>30mg/day, Olanzapine>20mg/day,        │         │
│                                                    │ Risperidone > 6mg/day, Quetiapine > 750mg/day)     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ A. Outpatient subjects, with no hospitalization    │ Subjects who have been treated with clozapine or   │      58 │
│ for worsening of schizophrenia within 3 months     │ long-acting injectable antipsychotic drugs within  │         │
│ prior to screening                                 │ 3 months prior to the screening                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects who have been treated more than 2 oral    │ Subjects who take atypical antipsychotic drugs,    │      58 │
│ antipsychotic drugs (including both typical and    │ and should be maintained on current antipsychotic  │         │
│ atypical antipsychotic drugs) with the minimum     │ drugs (including atypical antipsychotic drugs) and │         │
│ therapeutic effective dose (as specified in each   │ dose for at least 4 weeks prior to the screening   │         │
│ label) for schizophrenia treatment at screening    │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ (e.g. Aripiprazole\>30 mg/day, Olanzapine\>20      │ Subjects who have been treated over maximum        │      59 │
│ mg/day, Risperidone \> 6 mg/day, Quetiapine \> 750 │ maintenance dose (as specified in each label) of   │         │
│ mg/day)                                            │ oral antipsychotics at screening. (e.g.            │         │
│                                                    │ Aripiprazole>30mg/day, Olanzapine>20mg/day,        │         │
│                                                    │ Risperidone > 6mg/day, Quetiapine > 750mg/day)     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects who have been treated with oral           │ Subjects who have been treated with clozapine or   │      62 │
│ antipsychotic drugs (including both typical and    │ long-acting injectable antipsychotic drugs within  │         │
│ atypical antipsychotic drugs) exceeding maximum    │ 3 months prior to the screening                    │         │
│ maintenance dose (as specified in each label) at   │                                                    │         │
│ screening                                          │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects who were diagnosed of schizophrenia as    │ Subjects diagnosed of schizophrenia as defined by  │      64 │
│ defined by DSM diagnostic criteria, and were       │ Diagnostic and Statistical Manual of Mental        │         │
│ diagnosed of schizophrenia for at least for 2      │ Disorders, 4th edition text revision or 5th        │         │
│ years prior to screening                           │ edition (DSM-<U+2163>-TR or 5) criteria, and a     │         │
│                                                    │ history of illness for at least for 3 years prior  │         │
│                                                    │ to screening                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects who take atypical antipsychotic drugs     │ Subjects who take atypical antipsychotic drugs,    │      72 │
│ with the therapeutic effective dose (as specified  │ and should be maintained on current antipsychotic  │         │
│ in each label) for schizophrenia treatment, and    │ drugs (including atypical antipsychotic drugs) and │         │
│ should be maintained on the type and dose of the   │ dose for at least 4 weeks prior to the screening   │         │
│ current antipsychotic drugs (including both        │                                                    │         │
│ typical and atypical antipsychotic drugs) for at   │                                                    │         │
│ least 4 weeks prior to the screening               │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects with a current DSM diagnostic criteria-   │ Subjects with a current DSM-<U+2163>-TR or 5       │      84 │
│ based diagnosis other than schizophrenia,          │ diagnosis other than schizophrenia, including      │         │
│ including Schizoaffective disorder, major          │ schizoaffective disorder, major depressive         │         │
│ depressive disorder, bipolar disorder, delirium,   │ disorder, bipolar disorder, delirium, dementia,    │         │
│ neurocognitive disorder due to Alzheimer's or      │ amnesia, Borderline, Paranoid, Histrionic,         │         │
│ similar diseases, amnesia, borderline, paranoid,   │ Schizotypal, Schizoid, Antisocial or other         │         │
│ histrionic, schizotypal, schizoid, antisocial or   │ cognitive or personality disorders                 │         │
│ other cognitive or personality disorders           │                                                    │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only CHIA has the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Subjects who were diagnosed of schizophrenia as    │ Subjects must be capable of providing signed and   │      46 │
│ defined by DSM diagnostic criteria, and were       │ dated written informed consent by date of Visit 0  │         │
│ diagnosed of schizophrenia for at least for 2      │ (-2 week)                                          │         │
│ years prior to screening                           │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects who voluntarily consented to              │ Women who are pregnant, nursing, or who plan to    │      46 │
│ participating in the clinical trial                │ become pregnant while in the trial                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ (e.g. Aripiprazole\>30 mg/day, Olanzapine\>20      │ Subjects who have been treated over maximum        │      59 │
│ mg/day, Risperidone \> 6 mg/day, Quetiapine \> 750 │ maintenance dose (as specified in each label) of   │         │
│ mg/day)                                            │ oral antipsychotics at screening. (e.g.            │         │
│                                                    │ Aripiprazole>30mg/day, Olanzapine>20mg/day,        │         │
│                                                    │ Risperidone > 6mg/day, Quetiapine > 750mg/day)     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects who were diagnosed of schizophrenia as    │ Subjects diagnosed of schizophrenia as defined by  │      64 │
│ defined by DSM diagnostic criteria, and were       │ Diagnostic and Statistical Manual of Mental        │         │
│ diagnosed of schizophrenia for at least for 2      │ Disorders, 4th edition text revision or 5th        │         │
│ years prior to screening                           │ edition (DSM-<U+2163>-TR or 5) criteria, and a     │         │
│                                                    │ history of illness for at least for 3 years prior  │         │
│                                                    │ to screening                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects who take atypical antipsychotic drugs     │ Subjects who take atypical antipsychotic drugs,    │      72 │
│ with the therapeutic effective dose (as specified  │ and should be maintained on current antipsychotic  │         │
│ in each label) for schizophrenia treatment, and    │ drugs (including atypical antipsychotic drugs) and │         │
│ should be maintained on the type and dose of the   │ dose for at least 4 weeks prior to the screening   │         │
│ current antipsychotic drugs (including both        │                                                    │         │
│ typical and atypical antipsychotic drugs) for at   │                                                    │         │
│ least 4 weeks prior to the screening               │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects with a current DSM diagnostic criteria-   │ Subjects with a current DSM-<U+2163>-TR or 5       │      84 │
│ based diagnosis other than schizophrenia,          │ diagnosis other than schizophrenia, including      │         │
│ including Schizoaffective disorder, major          │ schizoaffective disorder, major depressive         │         │
│ depressive disorder, bipolar disorder, delirium,   │ disorder, bipolar disorder, delirium, dementia,    │         │
│ neurocognitive disorder due to Alzheimer's or      │ amnesia, Borderline, Paranoid, Histrionic,         │         │
│ similar diseases, amnesia, borderline, paranoid,   │ Schizotypal, Schizoid, Antisocial or other         │         │
│ histrionic, schizotypal, schizoid, antisocial or   │ cognitive or personality disorders                 │         │
│ other cognitive or personality disorders           │                                                    │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Levenshtein Ratio of Entire trial at once: 73
Average Levenshtein Ratio of individual lines: 69.75
OverAll Ratio: 71.375
